Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TY-9591 vs Osimertinib in EGFR-Mutated NSCLC With Brain Metastases
NCT05948813Phase 2Recruiting
- Sponsor
- TYK Medicines
- Start
- Aug 2023
- Primary completion
- Dec 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of asandeutertinib in non-small cell lung cancer (NSCLC), sponsored by TYK Medicines. Started Aug 2023; status: recruiting.
02
Drugs
asandeutertinib
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT05948813.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05948813.